IRIS

IRIS Advanced Search

Searches using filters for organ/system affected are limited to effects (or tumor sites) used to derive the RfD, RfC, oral slope factor, or inhalation unit risk. Other effects associated with chemicals in the IRIS database that were not used as the basis for a toxicity value are not searchable with organ/system filters. IRIS Advanced Search searches only final IRIS assessments; to look for information on draft assessments, see Quick Check: Assessments in Development.

Please use the filters on the left to search for assessments.

Search Filtered By:
cancer, noncancer, Nervous (Organ/System Affected)
Chemical Name CASRN Exposure Route Assessment Type Critical Effect or Tumor Type WOE Characterization Systems Affected or Tumor Site Toxicity Value Type Toxicity Value
Acephate 30560-19-1 Oral Noncancer Inhibition of brain ChE n/a Nervous RfD 4x10-3 mg/kg-day
Acetaldehyde 75-07-0 Inhalation Noncancer Degeneration of olfactory epithelium n/a Nervous RfC 9x10-3 mg/m3
Acetochlor 34256-82-1 Oral Noncancer Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males n/a Nervous RfD 2x10-2 mg/kg-day
Acrylamide 79-06-1 Oral Noncancer Degenerative nerve changes n/a Nervous RfD 2x10-3 mg/kg-day
Acrylamide 79-06-1 Inhalation Noncancer Degenerative nerve changes n/a Nervous RfC 6x10-3 mg/m3
Acrylic acid 79-10-7 Inhalation Noncancer Degeneration of the nasal olfactory epithelium n/a Nervous RfC 1x10-3 mg/m3
Acrylonitrile 107-13-1 Oral Cancer Brain and spinal cord astrocytomas, Zymbal gland carcinomas and stomach papillomas/ carcinomas B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines)
Nervous Oral Slope Factor 5.4x10-1
per mg/kg-day
Aldicarb 116-06-3 Oral Noncancer Sweating as clinical sign of AChe inhibition n/a Nervous RfD 1x10-3 mg/kg-day
Aldicarb sulfone 1646-88-4 Oral Noncancer Brain ChE inhibition in females n/a Nervous RfD 1x10-3 mg/kg-day
Allyl chloride 107-05-1 Inhalation Noncancer Functional and histological peripheral neurotoxicity n/a Nervous RfC 1x10-3 mg/m3
Baygon 114-26-1 Oral Noncancer Mild cholinergic symptoms and RBD ChE inhibition n/a Nervous RfD 4x10-3 mg/kg-day
Benzidine 92-87-5 Oral Noncancer Brain cell vacuolization; liver cell alterations in females n/a Nervous RfD 3x10-3 mg/kg-day
Biphenthrin 82657-04-3 Oral Noncancer Tremors n/a Nervous RfD 1.5x10-2 mg/kg-day
Bromomethane 74-83-9 Inhalation Noncancer Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity n/a Nervous RfC 5x10-3 mg/m3
Carbofuran 1563-66-2 Oral Noncancer RBC and plasma cholinesterase inhibition, and testicular and uterine effects n/a Nervous RfD 5x10-3 mg/kg-day
Carbon disulfide 75-15-0 Inhalation Noncancer Peripheral nervous system dysfunction n/a Nervous RfC 7x10-1 mg/m3
Chloral hydrate 302-17-0 Oral Noncancer CNS depression and GI irritation in humans n/a Nervous RfD 1x10-1 mg/kg-day
Chlorine cyanide 506-77-4 Oral Noncancer Weight loss, thyroid effects, and myelin degeneration n/a Nervous RfD 5x10-2 mg/kg-day
Chlorine dioxide 10049-04-4 Oral Noncancer Neurodevelopmental effects n/a Nervous RfD 3x10-2 mg/kg-day
Chlorite (sodium salt) 7758-19-2 Oral Noncancer Neurodevelopmental effects n/a Nervous RfD 3x10-2 mg/kg-day
Chlorobenzilate 510-15-6 Oral Noncancer Decreased stool quantity, food consumption and body weight gains hyperirritability (maternal effects) n/a Nervous RfD 2x10-2 mg/kg-day
Chloroprene 126-99-8 Inhalation Noncancer Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively n/a Nervous RfC 2x10-2 mg/m3
Cyanogen bromide 506-68-3 Oral Noncancer Weight loss, thyroid effects and myelin degeneration n/a Nervous RfD 9x10-2 mg/kg-day
Danitol 39515-41-8 Oral Noncancer Tremors n/a Nervous RfD 2.5x10-2 mg/kg-day
2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 1163-19-5 Oral Noncancer Neurobehavioral effects n/a Nervous RfD 7x10-3 mg/kg-day
Demeton 8065-48-3 Oral Noncancer ChE inhibition, optic nerve degeneration n/a Nervous RfD 4x10-5 mg/kg-day
Dichloroacetic acid 79-43-6 Oral Noncancer Lesions observed in the testes, cerebrum, cerebellum, and liver. n/a Nervous RfD 4x10-3 mg/kg-day
Dichlorvos 62-73-7 Oral Noncancer Plasma and RBC ChE inhibition in males and females brain ChE inhibition in males n/a Nervous RfD 5x10-4 mg/kg-day
Dichlorvos 62-73-7 Inhalation Noncancer Decreased brain cholinesterase activity n/a Nervous RfC 5x10-4 mg/m3
Dimethoate 60-51-5 Oral Noncancer Brain ChE inhibition n/a Nervous RfD 2x10-4 mg/kg-day
2,4-Dimethylphenol 105-67-9 Oral Noncancer Clinical signs (lethargy, prostration, and ataxia) and hematological changes n/a Nervous RfD 2x10-2 mg/kg-day
2,4-Dinitrotoluene 121-14-2 Oral Noncancer Neurotoxicity, Heinz bodies and biliary tract hyperplasia n/a Nervous RfD 2x10-3 mg/kg-day
1,4-Dioxane 123-91-1 Inhalation Noncancer Atrophy and respiratory metaplasia of the olfactory epithelium n/a Nervous RfC 3x10-2 mg/m3
Disulfoton 298-04-4 Oral Noncancer ChE inhibition, optic nerve degeneration n/a Nervous RfD 4x10-5 mg/kg-day
1,4-Dithiane 505-29-3 Oral Noncancer Nasal olfactory lesions n/a Nervous RfD 1x10-2 mg/kg-day
Endrin 72-20-8 Oral Noncancer Mild histological lesions in liver, occasional convulsions n/a Nervous RfD 3x10-4 mg/kg-day
Ethephon 16672-87-0 Oral Noncancer Plasma ChE inhibition n/a Nervous RfD 5x10-3 mg/kg-day
Ethion 563-12-2 Oral Noncancer Plasma cholinesterase inhibition n/a Nervous RfD 5x10-4 mg/kg-day
Ethyl p-nitrophenyl phenylphosphorothioate (EPN) 2104-64-5 Oral Noncancer Neurotoxicity n/a Nervous RfD 1x10-5 mg/kg-day
Fenamiphos 22224-92-6 Oral Noncancer ChE inhibition n/a Nervous RfD 2.5x10-4 mg/kg-day
Fonofos 944-22-9 Oral Noncancer Cholinesterase inhibition, cholinergic symptoms, and increased liver weight n/a Nervous RfD 2x10-3 mg/kg-day
2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) 68631-49-2 Oral Noncancer Neurobehavioral effects n/a Nervous RfD 2x10-4 mg/kg-day
Hexachloroethane 67-72-1 Inhalation Noncancer Neurotoxicity (tremors and ruffled pelt) n/a Nervous RfC 3x10-2 mg/m3
Hexachlorophene 70-30-4 Oral Noncancer Swollen salivary glands, status spongiosis in brain and optic nerve n/a Nervous RfD 3x10-4 mg/kg-day
Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Oral Noncancer Convulsions in F344 rats n/a Nervous RfD 4x10-3 mg/kg-day
1,6-Hexamethylene diisocyanate 822-06-0 Inhalation Noncancer Degeneration of olfactory epithelium n/a Nervous RfC 1x10-5 mg/m3
n-Hexane 110-54-3 Inhalation Noncancer Peripheral neuropathy (decreased MCV at 12 weeks) n/a Nervous RfC 7x10-1 mg/m3
2-Hexanone 591-78-6 Oral Noncancer Axonal swelling of the peripheral nerve n/a Nervous RfD 5x10-3 mg/kg-day
2-Hexanone 591-78-6 Inhalation Noncancer Motor conduction velocity of the sciatic-tibial nerve n/a Nervous RfC 3x10-2 mg/m3
Hydrogen sulfide 7783-06-4 Inhalation Noncancer Nasal lesions of the olfactory mucosa n/a Nervous RfC 2x10-3 mg/m3
Isobutyl alcohol 78-83-1 Oral Noncancer Hypoactivity and ataxia n/a Nervous RfD 3x10-1 mg/kg-day
Malathion 121-75-5 Oral Noncancer RBC ChE depression n/a Nervous RfD 2x10-2 mg/kg-day
Manganese 7439-96-5 Inhalation Noncancer Impairment of neurobehavioral function n/a Nervous RfC 5x10-5 mg/m3
Manganese 7439-96-5 Oral Noncancer CNS effects n/a Nervous RfD 1.4x10-1 mg/kg-day
Mepiquat chloride 24307-26-4 Oral Noncancer Sedation and tonoclonic spasms decreased food intake and body weights hematologic effects n/a Nervous RfD 3x10-2 mg/kg-day
Mercury, elemental 7439-97-6 Inhalation Noncancer Hand tremor; increases in memory disturbances; slight subjective and objective evidence of autonomic dysfunction n/a Nervous RfC 3x10-4 mg/m3
Merphos 150-50-5 Oral Noncancer Ataxia, delayed neurotoxicity and weight loss n/a Nervous RfD 3x10-5 mg/kg-day
Merphos oxide 78-48-8 Oral Noncancer Ataxia, delayed neurotoxicity and weight loss n/a Nervous RfD 3x10-5 mg/kg-day
Methamidophos 10265-92-6 Oral Noncancer ChE inhibition n/a Nervous RfD 5x10-5 mg/kg-day
Methanol 67-56-1 Inhalation Noncancer Reduced brain weight in rat pups at 6 weeks of age n/a Nervous RfC 2x101 mg/m3
Methyl chloride 74-87-3 Inhalation Noncancer Cerebellar lesions n/a Nervous RfC 9x10-2 mg/m3
Methyl methacrylate 80-62-6 Inhalation Noncancer Degeneration/ atrophy of olfactory epithelium (male rats) n/a Nervous RfC 7x10-1 mg/m3
Methyl parathion 298-00-0 Oral Noncancer RBC, ChE inhibition; reduced hemoglobin, hematocrit and RBCs n/a Nervous RfD 2.5x10-4 mg/kg-day
Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 Inhalation Noncancer Hyperplasia of olfactory epithelium n/a Nervous RfC 6x10-4 mg/m3
Methylmercury (MeHg) 22967-92-6 Oral Noncancer Developmental neuropsychological impairment n/a Nervous RfD 1x10-4 mg/kg-day
(High end of BMDL05 range)
Methylmercury (MeHg) 22967-92-6 Oral Noncancer Developmental neuropsychological impairment n/a Nervous RfD 1x10-4 mg/kg-day
(Low end of BMDL05 range)
2-Methylphenol 95-48-7 Oral Noncancer Decreased body weights and neurotoxicity n/a Nervous RfD 5x10-2 mg/kg-day
3-Methylphenol 108-39-4 Oral Noncancer Decreased body weights and neurotoxicity n/a Nervous RfD 5x10-2 mg/kg-day
Naled 300-76-5 Oral Noncancer Brain ChE inhibition n/a Nervous RfD 2x10-3 mg/kg-day
Naphthalene 91-20-3 Inhalation Noncancer Nasal effects: hyperplasia and metaplasia in respiratory and olfactory epithelium, respectively n/a Nervous RfC 3x10-3 mg/m3
Nitrobenzene 98-95-3 Inhalation Noncancer Bronchiolization of the alveoli and olfactory degeneration n/a Nervous RfC 9x10-3 mg/m3
2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) 60348-60-9 Oral Noncancer Neurobehavioral effects n/a Nervous RfD 1x10-4 mg/kg-day
Phosmet 732-11-6 Oral Noncancer Reduced body weight (males), liver cell vacuolation, cholinesterase inhibition n/a Nervous RfD 2x10-2 mg/kg-day
Pirimiphos-methyl 29232-93-7 Oral Noncancer Transient plasma ChE depression n/a Nervous RfD 1x10-2 mg/kg-day
Propham 122-42-9 Oral Noncancer Increase in male spleen weight and ChE depression in females n/a Nervous RfD 2x10-2 mg/kg-day
Propionaldehyde 123-38-6 Inhalation Noncancer Atrophy of olfactory epithelium n/a Nervous RfC 8x10-3 mg/m3
Propylene glycol monomethyl ether (PGME) 107-98-2 Inhalation Noncancer Mild reversible sedation n/a Nervous RfC 2 mg/m3
Pydrin 51630-58-1 Oral Noncancer Neurological dysfunction n/a Nervous RfD 2.5x10-2 mg/kg-day
Selenious acid 7783-00-8 Oral Noncancer Clinical selenosis n/a Nervous RfD 5x10-3 mg/kg-day
Selenium and Compounds 7782-49-2 Oral Noncancer Clinical selenosis n/a Nervous RfD 5x10-3 mg/kg-day
Silver cyanide 506-64-9 Oral Noncancer Weight loss, thyroid effects, and myelin degeneration n/a Nervous RfD 1x10-1 mg/kg-day
Styrene 100-42-5 Inhalation Noncancer CNS effects n/a Nervous RfC 1 mg/m3
2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) 5436-43-1 Oral Noncancer Neurobehavioral effects n/a Nervous RfD 1x10-4 mg/kg-day
Tetrachloroethylene 127-18-4 Oral Noncancer (See Note) n/a Nervous RfD 6x10-3 mg/kg-day
Tetrachloroethylene 127-18-4 Inhalation Noncancer (See Note) n/a Nervous RfC 4x10-2 mg/m3
Tetrachlorovinphos 961-11-5 Oral Noncancer Reduced body weight gain, increased liver and kidney weights, and RBC ChE inhibition n/a Nervous RfD 3x10-2 mg/kg-day
Tetraethyldithiopyrophosphate 3689-24-5 Oral Noncancer Depressed RBC and plasma cholinesterase activity n/a Nervous RfD 5x10-4 mg/kg-day
Tetrahydrofuran 109-99-9 Inhalation Noncancer Increased liver weight and centrilobular cytomegaly, CNS effects (narcosis) n/a Nervous RfC 2 mg/m3
Thiram 137-26-8 Oral Noncancer Neurotoxicity n/a Nervous RfD 5x10-3 mg/kg-day
Toluene 108-88-3 Inhalation Noncancer Neurological effects in occupationally-exposed workers n/a Nervous RfC 5 mg/m3
1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113) 76-13-1 Oral Noncancer Psychomotor impairment n/a Nervous RfD 3x101 mg/kg-day
1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a Nervous RfC 5 mg/m3
(Short-term)
1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a Nervous RfC 6 mg/m3
(Acute: 24 hours)
1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a Nervous RfC 9 mg/m3
(Acute: 1 hour)
1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a Nervous RfC 7 mg/m3
(Acute: 4 hours)
1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a Nervous RfC 7 mg/m3
(Acute: 8 hours)
1,2,3-Trimethylbenzene 526-73-8 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a Nervous RfD 4x10-2 mg/kg-day
(Subchronic)
1,2,3-Trimethylbenzene 526-73-8 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a Nervous RfC 2x10-1
(Subchronic)
1,2,3-Trimethylbenzene 526-73-8 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a Nervous RfC 6x10-2 mg/m3
(Chronic)
1,2,3-Trimethylbenzene 526-73-8 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a Nervous RfD 1x10-2 mg/kg-day
(Chronic)
1,2,4-Trimethylbenzene 95-63-6 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a Nervous RfD 1x10-2 mg/kg-day
(Chronic)
1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a Nervous RfC 2x10-1 mg/m3
(Subchronic)
1,2,4-Trimethylbenzene 95-63-6 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a Nervous RfD 4x10-2 mg/m3
(Subchronic)
1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a Nervous RfC 6x10-2 mg/m3
(Chronic)
1,3,5-Trimethylbenzene 108-67-8 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a Nervous RfC 6x10-2 mg/m3
(Chronic)
1,3,5-Trimethylbenzene 108-67-8 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a Nervous RfD 1x10-2 mg/kg-day
(Chronic)
1,3,5-Trimethylbenzene 108-67-8 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a Nervous RfC 2x10-1 mg/m3
(Subchronic)
1,3,5-Trimethylbenzene 108-67-8 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a Nervous RfD 4x10-2 mg/kg-day
(Subchronic)
Vinyl acetate 108-05-4 Inhalation Noncancer Nasal epithelial lesions n/a Nervous RfC 2x10-1 mg/m3
Xylenes 1330-20-7 Inhalation Noncancer Impaired motor coordination (decreased rotarod performance) n/a Nervous RfC 1x10-1 mg/m3
Zinc cyanide 557-21-1 Oral Noncancer Weight loss, thyroid effects, and myelin degeneration n/a Nervous RfD 5x10-2 mg/kg-day
n-Butanol 71-36-3 Oral Noncancer Hypoactivity and ataxia n/a Nervous RfD 1x10-1 mg/kg-day